Figure 4 Cerebrospinal fluid levels of neurofilament light chain

Slides:

Advertisements

Similar presentations

A 67-year-old male with behavioral and language problems

Advertisements

Parkinson’s Plus By: Glen Estrosos.

Alzheimer’s Disease. Alzheimer's is a the most common form of dementia. Nearly 50-80% of all dementia patients have Alzheimer's. It is a progressive fatal.

Focal Syndromes Dr Stephen Pearson Consultant in Old Age Psychiatry Devon Partnership Trust.

Kimiko Domoto-Reilly, MD Cognitive / Behavioral Neurology Fellow Massachusetts General Hospital & Brigham and Women’s Hospital.

CPC #7: Pathology Barbara J. Crain, MD, PhD February 25, 2009.

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

What we are learning about Alzheimer’s disease genetics Bryan J. Traynor.

AFTD Education Conference Research Update: Focus on Two Large Federally Funded Projects: LEFFTDS and ARTFL David Knopman MD Neurology Mayo Clinic Rochester.

Frontotemporal Lobar Degeneration:

FRONTOTEMPORAL DEMENTIA IN A CASE OF SUICIDAL HANGING

Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy Rosa Capozzo, Celeste Sassi, Monia B. Hammer,

Nat. Rev. Neurol. doi: /nrneurol

Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints Argonde C. van Harten, Pieter Jelle Visser,

Frontotemporal dementia syndromes are united by underlying frontotemporal lobar degeneration pathology, which can be divided according to the presence.

Fig. 11. Algorithm for differential diagnosis of cognitive impaired subjects by employing structural imaging. AD = Alzheimer's disease, BG = basal ganglia,

A 66 year-old woman with progressive speech difficulty

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Life expectancy at birth in all countries included

Figure 1 Perivenous distribution of multiple sclerosis lesions

Nat. Rev. Neurol. doi: /nrneurol

PPMI in the Medical Literature

Figure 2 The US Centers for Disease Control and

Figure 4 Time course of the development of physiological changes

Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD)

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Overview of risk factors for Parkinson disease dementia

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Patterns of brain atrophy in Alzheimer disease

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Figure 2 Grey matter atrophy in FTD

Figure 2 Flow chart of patients who met the inclusion/exclusion criteria for the study Flow chart of patients who met the inclusion/exclusion criteria.

Figure 1 Associations between baseline cerebrospinal fluid

Mark S. Forman, Virginia M-Y. Lee, John Q. Trojanowski Neuron

Figure 6 Imaging methods used to study Parkinson disease

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Precision medicine based on a network approach

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

Volume 91, Issue 1, Pages (July 2016)

Figure 3 Ascending pain pathways and the brain regions involved

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Genetic pleiotropy in ALS

Figure 1 Evolution of multiple sclerosis

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 VEGF in neurodegenerative disease

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biomarkers associated with different clinical phases in MS

Figure 3 Potential interplay between physiological

Transmissible human proteopathies: an expanding field

Volume 91, Issue 1, Pages 1-3 (July 2016)

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Rett syndrome severity and age at diagnosis by mutation type

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Overview of the imaging biomarker roadmap

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Percentage distribution according to severity of baseline behavioral changes in behavioral variant frontotemporal dementia (bvFTD) and semantic.

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Network connections of the hypothalamus

Figure 2 Model representations of performance on functional and behavioral measures over time for behavioral variant frontotemporal dementia (bvFTD) and.

Progression and survival analysis.

STK11/LKB1 genetic alterations are associated with shorter progression-free and overall survival with PD-1 blockade among KRAS-mutant LUAC in the SU2C.

Presentation transcript:

Figure 4 Cerebrospinal fluid levels of neurofilament light chain Figure 4 | Cerebrospinal fluid levels of neurofilament light chain. a | Cerebrospinal fluid (CSF) levels of neurofilament light chain (NfL) in clinical frontotemporal dementia (FTD) subtypes and other neurodegenerative diseases; horizontal lines represent medians. b | Kaplan–Meier survival curves stratified for CSF NfL levels in tertiles; vertical ticks represent censored data (patients known to be alive at that time from CSF collection). c | CSF levels of NfL in presymptomatic and symptomatic genetic FTD of the three major genes (GRN, C9orf72 and MAPT), including two individuals who converted from the presymptomatic to symptomatic stage (connecting line). AD, Alzheimer disease; bvFTD, behavioural variant frontotemporal dementia; CBS, corticobasal syndrome; MND, motor neuron disease; nfvPPA, nonfluent variant primary progressive aphasia; PD, Parkinson disease; PSP, progressive supranuclear palsy; svPPA, semantic variant primary progressive aphasia. Part a modified with permission from Wiley & Sons © Scherling, C. S. et al. Ann. Neurol. 75, 116–126 (2014). Parts b–c modified with permission from Wiley & Sons © Meeter, L. H. et al. Ann. Clin. Transl. Neurol. 3, 623–636 (2016) under a Creative Commons license. Part a modified with permission from Wiley & Sons © Scherling, C. S. et al. Ann. Neurol. 75, 116–126 (2014). Parts b–c modified with permission from Wiley & Sons © Meeter, L. H. et al. Ann. Clin. Transl. Neurol. 3, 623–636 (2016) under a Creative Commons license. Meeter, L. H. et al. (2017) Imaging and fluid biomarkers in frontotemporal dementia Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.75